Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 3, 2009, Pages 375-382

  Mantzaris, Gerassimos J ^a   Christidou, Angelika ^a   Sfakianakis, Michael ^b   Roussos, Anastassios ^a   Koilakou, Stavroula ^a   Petraki, Kalliopi ^c   Polyzou, Paraskevi ^a  

^a EVANGELISMOS HOSPITAL   (Greece)

^b METROPOLITAN HOSPITAL   (Greece)

^c UNIVERSITY OF PIRAEUS   (Greece)

Author keywords

Azathioprine; Budesonide; Crohn's disease; Histologic remission; Mucosal healing

Indexed keywords

AZATHIOPRINE; BUDESONIDE; PREDNISOLONE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACNE; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON MUCOSA; COLONOSCOPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HAIR LOSS; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; LEUKOCYTE COUNT; LEUKOPENIA; LOW DRUG DOSE; MALE; MOON FACE; PANCREATITIS; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; WOUND HEALING; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG RESISTANCE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; INTESTINE MUCOSA; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BUDESONIDE; CROHN DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66149148366     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20777     Document Type: Article

References (38)

1. Casellas F, Lópes-Vivancos J, Vergara M, et al. Impact of inflammatory bowel disease on health-related quality of life. Dig Dis. 1999;17:208-218.
2. Guassora AD, Kruuse C, Thomsen OØ, et al. Quality of life study in a regional group of patients with Crohn's disease. A structured interview study. Scand J Gastroenterol. 2000;35:1068-1074.
3. Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-260.
4. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther. 2006;24:319-330.
5. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132-142.
6. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215-219.
7. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50:485-489.
8. Sandborn WJ, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission of Crohn's disease. Cohrane Database Syst Rev. 2000;2:CD000545.
9. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med. 2000; 342:1627-1632.
10. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002;359: 1541-1549.
11. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442.
12. Lichtenstein GR, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005;128:862-869.
13. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
14. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
15. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. Gastroenterology. 1990;98:811-818.
16. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's Disease: TREAT Registry. Clin Gastroenterol Hepatol. 2006; 4:621-630.
17. Rutgeerts P, Löfberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994;331: 842-845.
18. Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut. 1997; 41:209-214.
19. Sandborn WJ, Feagan BG, Lichtenstein GR. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission. Aliment Pharmacol Ther. 2007;26:987-1003.
20. Cortot A, Colombel JF, Rutgeerts P, et al. Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn's disease. Gut. 2001;48:186-190.
21. Andus T, Gross V, Caesar I, et al, for the German-Austrian Budesonide Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig Dis Sci. 2003; 48:373-378.
22. Greenberg GR, Feagan BG, Martin F, et al, for the Canadian Inflammatory Bowel Disease Group. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Gastroenterology. 1996;110:45-51.
23. Löfberg R, Rutgeerts P, Malchow H, et al. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study. Gut. 1996;39:82-86.
24. Mantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease. Clin Gastroenterol Hepatol. 2003;1:122-128.
25. Green JR, Lobo AJ, Giaffer M, et al, Freedom Investigator Group. Maintenance of Crohn's disease over 12 months: fixed versus flexible dosing regimen using budesonide controlled ileal release capsules. Aliment Pharmacol Ther. 2001;15:1331-1341
26. Sandborn WJ, Van Os EC, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology. 1995;109:1808-1817.
27. D'Haens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology. 1997;112:1475-1481.
28. D'Haens G, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
29. D'Haens G, Geboes K, Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointest Endosc. 1999; 50:667-671.
30. Lémann M, Mary JY, Colombel JF, et al, Groupe D'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812-1818.
31. Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70:439-444.
32. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989; 96:804-810.
33. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du tube Digestif (GETAID). Gut. 1989;30:983-989.
34. STSC PLUS*WARE software product. Stagraphics user's guide. Rockville, MD: STSC, 1986.
35. Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery, Gut. 2005;54:237-241.
36. Vermeire S, Van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn's disease - evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12.
37. D'Haens G, Baert F, van Assche G, et al, Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371: 660-667.
38. Lémann M, Mary JY, Duclos B, et al; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054-1061.